Ispire Technology Inc. (ISPR) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2025 (Q2 Fiscal 2026). Ispire Technology Inc. is engaged in the research, development, and distribution of branded e-cigarettes and cannabis vaping hardware. The company operates globally, with significant manufacturing in Malaysia and sales operations in Europe, North America, and Asia. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Revenue | $20.29 million | $50.64 million |
| Gross Profit | $3.47 million (17.1% margin) | $8.62 million (17.0% margin) |
| Net Loss | $(6.60) million | $(9.86) million |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.17) |
| Cash and Restricted Cash | $17.62 million (as of Dec 31, 2025) | N/A |
| Total Debt (Current + Non-Current) | $1.38 million | N/A |
| Related Party Payables | $42.44 million (Current) + $29.00 million (Non-Current) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 51.5% year-over-year for the quarter and 37.6% for the six-month period. The decline was driven by a $9.3 million drop in U.S. sales (due to stricter credit terms) and a $9.2 million drop in European sales (due to competitive market conditions).
- Margin Compression: Gross margin decreased from 18.5% to 17.1% for the quarter, attributed to a shift in product mix toward lower-margin items.
- Expense Reduction: Operating expenses decreased 31.4% for the quarter, primarily due to reduced headcount in North America, lower stock-based compensation, and decreased marketing/travel spend.
- Credit Losses: Credit loss expenses remained significant at $4.21 million for the quarter, though they decreased 18.0% for the six-month period compared to the prior year due to improved collections.
- Stockholders' Equity: The company moved from a positive equity position of $0.60 million at June 30, 2025, to a deficit of $(7.66) million at December 31, 2025, due to accumulated net losses.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash and operating cash flows are sufficient to meet working capital needs for the next 12 months. However, the company relies heavily on related party payables (owed to Shenzhen Yi Jia, controlled by the CEO) for liquidity.
- Regulatory Risks: Significant risks remain regarding FDA Premarket Tobacco Product Applications (PMTAs) in the U.S. and evolving regulations in Europe (TPD). The company has largely ceased marketing tobacco products in the U.S. due to regulatory costs.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2025. Material weaknesses were identified regarding the evaluation of significant estimates (inventory and credit loss reserves), lack of sufficient accounting personnel, and IT general controls.
- Joint Venture: The company has a committed investment of up to $10 million in IKE Tech LLC (an age-verification joint venture), with $5.3 million currently unpaid and recorded as a liability.
Investor Verification Checklist
- Related Party Dependence: Verify the sustainability of operations given that 97% of purchases come from a related party (Shenzhen Yi Jia) and significant liabilities are owed to this entity.
- Credit Quality: Assess the adequacy of the $20.9 million allowance for credit losses against the $58.7 million gross accounts receivable balance.
- Internal Control Remediation: Review the specific steps management is taking to remediate the material weaknesses in financial reporting controls identified in Item 4.
- Regulatory Status: Confirm the status of PMTA applications for U.S. market access and the impact of European TPD compliance on future revenue.
- Cash Burn: Monitor the net cash used in operating activities ($5.15 million for the six months) against the current cash balance of $17.6 million to determine runway.